Solid organ transplant recipients have a high incidence of central nervous system (CNS) complications, including both focal and diffuse neurologic deficits. In the immunocompromised host, the initial clinical evaluation must focus on both life-threatening CNS infections and vascular or anatomic lesions. The clinical signs and symptoms of CNS processes are modified by the immunosuppression required to prevent graft rejection. In this population, these etiologies often coexist with drug toxicities and metabolic abnormalities that complicate the development of a specific approach to clinical management. This review assesses the multiple risk factors for CNS processes in solid organ transplant recipients and establishes a timeline to assist in the evaluation and management of these complex patients.
Between 10% and 85% of solid organ transplant recipients develop central nervous system (CNS) abnormalities, with presentations ranging from generalized encephalopathy or headache to focal neurologic deficits [1] [2] [3] . The etiology of these abnormalities is often obscure; symptoms are altered by immunosuppressive therapy. There is urgency to establish a specific etiologic diagnosis to guide therapy. The major categories of "CNS processes" include infection, drug toxicity, anatomic processes (stroke, cancer, vasculitis), and metabolic abnormalities including those associated with graft dysfunction. These etiologies often coexist in the transplant recipient. For example, posttransplant graft dysfunction (uremia, cardiac, or hepatic insufficiency; hypoxia) can be complicated by infection (sepsis, wound infection, nosocomial pneumonia), drug toxicity (CNS effects of calcineurin inhibitors), stroke, or bleeding. The initial evaluation must identify potentially lifethreatening processes.
INFECTIOUS RISK
The risk for infection after transplantation rests on two fundamental determinants: prior exposures and the net state of immunosuppression [4, 5] . The epidemiologic exposures of a transplant recipient include those from the hospital environment, from community exposures, from the host as reactivation of latent infections, and from the organ donor. The "net state of immunosuppression" is a concept encompassing patient-specific factors that determine vulnerability to infection [4] .
EPIDEMIOLOGIC EXPOSURES

Donor-Derived Infection
A variety of infectious and noninfectious (eg, cancer) processes have been transmitted through transplant (Table 1) [6, [10] [11] [12] [13] [14] . Transmission of viruses (eg, herpes simplex virus [HSV] ) from viremic donors, parasites (Balamuthia), or fungi (eg, Aspergillus species or Cryptococcus neoformans) with contaminated organs may manifest as brain abscess or meningitis [14] . Several CNS pathogens have been implicated recently in donor-derived infections when donor testing for the specific pathogen was not routinely performed. Donorderived transmissions of West Nile Virus, rabies virus, and lymphocytic choriomeningitis virus have been documented [15] [16] [17] Some of these infections were masked in the donor by concomitant CNS processes (stroke, hemorrhage); others resulted from improper performance of donor screening assays or miscommunication of data [18, 19] . Serologic testing of donors for human T-cell lymphotropic virus type 1 (HTLV-1), the agent of HTLV-1-associated myelopathy, is no longer required in the United States. Controversy exists regarding the use of organs from donors with undiagnosed or untreated meningitis or encephalitis prior to organ procurement [20] [21] [22] [23] [24] .
Hospital Environment
Transplant recipients with prolonged pretransplant hospitalizations and with exposures to multiple courses of antimicrobial agents may become colonized with nosocomial flora including Aspergillus species with CNS infection manifesting in the posttransplant period [25, 26] . Empiric antimicrobial therapies in recipients with CNS symptoms must account for prior antimicrobial exposures and colonization [27, 28] . Among these are fluoroquinolone-resistant streptococci in patients receiving these agents for prophylaxis.
Community Exposures
In the community, diverse, common exposures including Streptococcus pneumoniae, Mycobacterium tuberculosis, Lyme disease, or C. neoformans, may present with confusion, headache, or focal neurologic deficits. Infectious exposures also result from contaminated water or food sources (eg, Listeria monocytogenes, see Figure 1 ), social contacts (eg, Epstein-Barr virus [EBV], see Figure 2 ), gardening (molds including the agents of mucormycosis and Scedosporium species, see Figure 3 ), pets (eg, C. neoformans, Toxoplasma gondii), and travel (eg, Coccidioides immitis) [29, 30] . Thus, the recent and remote epidemiologic history may suggest an etiologic diagnosis for CNS infection. Important community-acquired pathogens associated with CNS infection are presented in Table 2 . Strongyloides stercoralis can cause polymicrobial or gram-negative bacteremia and meningitis with the hyperinfection syndrome in immunocompromised hosts decades after the initial exposure [32, 33] . Community outbreaks disproportionately affect transplant recipients in incidence and clinical severity, as with recent outbreaks of West Nile virus with meningoencephalitis [15, [34] [35] [36] .
Reactivation of Recipient Infections
Pretransplant screening of transplant candidates may suggest etiologies for CNS processes. Herpesvirus seropositivity is a marker for lifelong infection; the risk for reactivation is dependent on the intensity of immunosuppression. Thus, meningoencephalitis with HSV or varicella zoster virus (VZV) is a consideration in the immunosuppressed, seropositive recipient. Screening practices vary by organ and with national guidelines; testing for all potential CNS pathogens is not routine (eg, T. gondii in non-cardiac transplant candidates) [37] . Routine screening of transplant candidates is outlined in Table 3 . A group of pathogens, including Aspergillus, Cryptococcus, and Nocardia species, cause "pulmonary-brain syndromes" beginning with respiratory tract colonization and CNS metastasis [38] . Screening for colonization is not routine but may be detected on review of existing microbiologic data.
NET STATE OF IMMUNOSUPPRESSION
The net state of immunosuppression is largely defined by the immunosuppressive regimen. The risk for infection is dependent on the dose and sequence of specific agents. The sequence [6] [7] [8] [9] .
is also important when considering drug toxicity as a cause of CNS symptoms. The role of infection in such syndromes may be suggested by the timing of symptoms in relation to changes in the type or intensity of immunosuppression. Intensification of immunosuppression in the initial posttransplant course (induction therapy) or for treatment of graft rejection risks infection more than stable regimens (maintenance therapy). Specific regimens pose unique infectious risks including the association between complement inhibition (eg, eculizumab) or hypogammaglobulinemia with antibody or B-cell depletion (eg, plasmapheresis) and encapsulated bacteria (S. pneumoniae, Haemophilus influenza, meningococcus) [39, 40] .
The net state of immunosuppression is also influenced by coexisting medical conditions including cirrhosis, diabetes, or chronic sinusitis. Pretransplant immunosuppressive therapies, including corticosteroids, biologic agents, or antimetabolites for autoimmune processes, will add to the overall risk. These factors increase susceptibility to infection and accentuate the impact of anatomic deficits such as chronic sinusitis, providing a CNS portal for colonizing pathogens.
Ongoing infection may coexist with other CNS abnormalities. Cytomegalovirus (CMV) may cause CNS infection (ie, CMV retinitis or meningoencephalitis) [41] [42] [43] . EBV may cause aseptic meningitis, seizures, encephalitis, or posttransplant lymphoproliferative disorder (PTLD) (Figure 2 ) [44, 45] . Multiple viruses (CMV, EBV, hepatitis C virus [HCV]) are associated with increased risk for other opportunistic infections via modulation of the host immune response [46] [47] [48] [49] . Such viral infections may merit therapy in patients with CNS symptoms but cannot preclude evaluation for other coexisting processes.
NONINFECTIOUS CONSIDERATIONS
Noninfectious causes of CNS abnormalities fall into 3 general categories: metabolic derangements, anatomic processes, and drug toxicities.
Metabolic Derangements
In the immediate postoperative period, metabolic derangements are common due to organ dysfunction and perioperative fluid and electrolyte shifts. For example, liver transplant patients may have ongoing hepatic encephalopathy or, rarely, central pontine myelinolysis from overly rapid correction of hyponatremia [50, 51] . Alcoholic liver recipients regain normal mental function more slowly than do other groups [52] [53] [54] . Cardiothoracic recipients may be hypoxemic with fluid overload or graft dysfunction. Bypass surgery (in heart, lung, and some liver recipients) can result in diminished mental capacity postoperatively [55] . These common metabolic changes coupled with routine perioperative medications complicate evaluation of CNS syndromes early after transplant.
Altered mental status may present at any time following transplant in association with graft dysfunction (eg, metabolic changes due to organ dysfunction during rejection) or Figure 3 . MRI scan in a 72-year-old man with history of diabetes and nonischemic cardiomyopathy requiring ventricular assist device and 2 months after heart transplant current medications included (tacrolimus, mycophenolate mofetil, and prednisone). He presented with 3 days of nausea and vomiting, diarrhea, headaches, confusion, and generalized seizure without fever. Magnetic resonance imaging with contrast revealed an irregular ring-enhancing lesion in the left occipital lobe with central restricted diffusion (arrow). Biopsy of the lesion revealed Scedosporium apiospermum brain abscess. He was subsequently found to have mitral valve endocarditis with Scedosporium species. Abbreviation: MRI, MR Image. medication toxicity (eg, renal or hepatic toxicity, hypotension, posttransplant diabetes). Technical complications (eg, obstruction, anastomotic leaks, or bleeding) may also contribute to graft dysfunction. Because graft rejection, infection, and associated metabolic derangements commonly occur simultaneously, imaging and invasive testing including graft biopsy and lumbar puncture may be necessary to determine the contribution of each to neurologic processes [56] [57] [58] .
Drug Side Effects
Perioperative anesthesia and pain management impact mental status. Subsequently, many drugs including immunosuppressive agents and antimicrobial prophylaxis are neurotoxic. Calcineurin inhibitors (tacrolimus, cyclosporine) cause effects ranging from headache and tremors to CNS vasculitis, seizures, and posterior reversible leukoencephalopathy syndrome [59] . Drug reactions are dose-and level-related or idiosyncratic; metabolic abnormalities, including hypomagnesemia, potentiate CNS effects. Drugs that interact with the calcineurin inhibitors may raise levels (eg, azole antifungal agents, diltiazem) provoking toxicity or infection [60] . Alternatively, interactions may decrease drug levels (eg, rifampin), provoking graft rejection [61] . Subsequent intensification of immunosuppression risks infection. Many antibiotics have diverse CNS side effects. The β-lactam antibiotics may cause confusion, hallucinations, encephalopathy, or seizures [62] . Trimethoprim-sulfamethoxazole (TMP-SMX) uncommonly causes encephalopathy or aseptic meningitis [63] . Fluoroquinolones are associated with neurological disorders from headache, confusion, and psychosis to nonconvulsive status epilepticus [63] [64] [65] [66] [67] . Metronidazole occasionally causes cerebellar ataxia and dysarthria [68, 69] . Some effects are due to overdosing with renal insufficiency whereas others are idiosyncratic [63, 64, 70] .
Anatomic Abnormalities
Space-occupying lesions of the CNS occur with infection, malignancy, or bleeding. Transplant patients have double the general cancer risk, particularly skin cancers and others associated with viral infection [71] . Thus, seronegative recipients for EBV pretransplant with seropositive donors are at increased risk for PTLD; EBV viremia or lymphocytosis may suggest PTLD [72] [73] [74] .
Although coagulopathy and stroke are seen in recipients of all organs, lung and heart recipients are at particular risk for peritransplant events following cardiopulmonary bypass and iatrogenic adjustments in coagulation [75, 76] . Cerebrovascular disease is also increased by chronic immunosuppression [77, 78] . Atypical infections may be associated with masses or strokes including embolic stroke with endocarditis or hemorrhagic stroke with angioinvasive fungal infection [79] [80] [81] .
Vasculitis
Distinction between autoimmune disease, graft rejection, and PTLD can be difficult. Despite immunosuppression, CNS autoimmune diseases including systemic lupus, optic neuritis, and giant cell arteritis may emerge in immunosuppressed recipients [82, 83] . Triggers for CNS autoimmune diseases include concurrent infections or drug side effects [84] [85] [86] Caution is warranted in treating clinical syndromes suggestive of autoimmune CNS processes, as these may reflect underlying infection, drug toxicity, or malignancy; increased immunosuppression may provoke deleterious outcomes [86] . Migraine headache may also emerge in the postoperative setting.
THE TIMELINE OF CNS PROCESSES
Multiple factors contribute to altered mental status and neurologic disorders in the posttransplant setting [7] . The intersection of epidemiology and the net state of immunosuppression characterizes the evolving risk for CNS infections. Variability exists with immunosuppressive regimens, antimicrobial prophylaxis, and epidemiology. Superimposed are the effects of metabolic abnormalities and drug toxicities. This approach creates a timeline for common and more obscure posttransplant CNS syndromes (Table 4) .
POSTOPERATIVE PHASE (1-4 WEEKS)
In the first month after transplant, traditional opportunistic infections are unexpected without pretransplant immunosuppression or specific risk factors including recent hospitalizations. Infection and metabolic derangements contribute to altered mental status. Postsurgical complications are common including surgical site infections, anastomotic leaks, Clostridium difficile colitis, or pneumonia, and may cause metastatic infection and metabolic abnormalities [96] . Development of opportunistic CNS infections in the early posttransplant period requires either an intensive epidemiologic exposure (large organism burden) or anatomic predisposition (eg, sinopulmonary infection). Thus, CNS aspergillosis (via hospital construction or sinus colonization) or Legionella pneumophila pneumonia (eg, via contaminated air-conditioning systems) may occur. Donor-derived infections, notably with neurotropic viruses, may present with extraordinary virulence in the first 1-3 weeks after transplant [12] . Many CNS symptoms relate to drug toxicity during introduction of immunosuppression and antimicrobial prophylaxis. Calcineurin inhibitor (CNI) levels increase with azole antifungal agents, macrolide antibiotics (erythromycin, clarithromycin), calcium channel blockers, and some selective serotonin reuptake inhibitors. The CNI may cause headaches, confusion, tremors, seizures, peripheral neuropathy, cerebellar syndrome, cortical blindness, or posterior leukoencephalopathy. Withdrawal of corticosteroids may provoke adrenocortical deficiency with altered mental state and metabolic derangements. Alcohol withdrawal may emerge postoperatively with weaning of anesthesia. Removal of existing psychiatric therapies may unmask posttransplant depression or other symptoms.
EARLY POSTTRANSPLANT SYNDROMES (1-6 MONTHS)
The peak period for opportunistic infections affecting the CNS is 1-6 months after transplant. Many common infections are prevented by routine prophylaxis. Daily TMP-SMX prevents many common CNS infections including L. monocytogenes, T. gondii, and Nocardia species. Alternative regimens (eg, atovaquone or pentamidine) do not provide this spectrum of coverage [97, 98] . Herpesvirus infections (CMV, HSV, EBV, VZV) are uncommon during adequate anti-CMV prophylaxis. Depending on epidemiology and the transplanted organ (eg, lungs), azole antifungal prophylaxis may provide protection against important CNS pathogens including Aspergillus species, C. neoformans, and endemic fungi such as Histoplasma or Coccidioides [99, 100] . Infections due to other molds including Scedosporium and the Mucorales are increasingly recognized ( Figure 3) [7, 87, 101] . Tuberculosis may involve the CNS during this period [102] .
LATE POSTTRANSPLANT CNS SYNDROMES (6 MONTHS AND BEYOND)
Generally, 6 months after transplant, immunosuppression and associated toxicities have been tapered and metabolic considerations cleared. The main causes of CNS syndromes include disseminated infection, tumor, or metabolic abnormalities during graft dysfunction. Special considerations include recipients with recurrent diseases (HCV, proteinuria), pancreas/islet recipients (symptomatic hypoglycemic episodes or pancreatitis), and anastomotic complications (strictures). Infectious risk after cessation of prophylaxis is determined by immunosuppression and epidemiology. CNS pathogens include common agents such as herpesviruses, bacteria (eg, S. pneumoniae), cryptococcosis, and invasive molds. However, uncommon CNS pathogens of immunocompromised hosts (eg, Strongyloides, toxoplasmosis, tuberculosis) may emerge. In the absence of effective vaccination or immunity, measles and mumps infections may occur. Anatomic abnormalities (eg, sinopulmonary disease, endocarditis) may provoke CNS infection; uncommonly, polymicrobial brain abscesses may occur [103, 104] . Pulmonary-brain syndromes and embolic disease merit consideration. New exposures (travel, gardening, sexual partners, or foods) should be considered.
Changes in the immunosuppression history may suggest a role for drug toxicity or for new infection following treatment of graft rejection. Patients requiring persistently intensive immunosuppression and those with recurrent viral infections are at greater risk for atypical processes including progressive multifocal leukoencephalopathy (PML) from JC polyomavirus (see Figure 2 ) [105] .
EVALUATION OF THE TRANSPLANT PATIENT WITH CNS SYMPTOMS
A specific diagnosis of CNS processes in transplant recipients is essential for management. Empiric therapy risks drug toxicities and interactions. Reduced immunosuppression may provoke or exacerbate graft rejection. The usual signs of CNS processes are often muted [106, 107] . Despite meningitis, Kernig and Brudzinski signs are often absent; subtle cranial nerve findings may be evident (Table 5 ). Immunosuppressed patients with focal neurologic deficits require urgent brain imaging. Most transplant recipients with altered mental status also require imaging. Computed tomography or magnetic resonance imaging studies without contrast (to preserve renal function) may demonstrate mass lesions but lack sensitivity for white matter changes [111] . Calcineurin inhibitor levels or metabolic assessment may suggest an etiology for dysfunction; however, those with fever or without a clear source of their defects also require cerebrospinal fluid (CSF) examination, ideally prior to antimicrobial therapy. CSF examination should always include cell counts and differential; routine smears and cultures for bacteria, fungi, and mycobacteria; and HSV DNA, cryptococcal antigen, and syphilis studies. Larger volumes increase the sensitivity of culture data from lumbar puncture [113] . Cell counts may be altered by immunosuppression or leukopenia [107, [114] [115] [116] . Stored CSF allows future analyses including novel tests such as 16S ribosomal RNA or high-throughput DNA sequencing [117] . Repeat CSF studies may be useful as symptoms evolve.
Extraneural lesions (eg, pulmonary, lymph node, or skin) may suggest metastatic infection or malignancy based on cultures or histopathology. However, biopsies of brain lesions should be considered if other studies are unrevealing. PTLD or PML may occur in the absence of high levels of circulating EBV or JC virus. Serum fungal markers have not been well studied in the diagnosis of CNS infections; galactomannan antigen testing has not been generally useful in the solid organ transplant recipient, and false-positive testing may complicate management [118] [119] [120] Serologic studies are generally slow to evolve in transplantation, and may be unreliable [121, 122] . Inquiries should be made to the local organ procurement organization about the status of recipients receiving organs from the same donor.
MANAGEMENT CONSIDERATIONS
If infection is suspected as the etiology of a CNS syndrome, following blood and CSF cultures, empiric broad-spectrum antimicrobial therapy can be instituted for bacterial (including pneumococcus and Listeria), fungal (including Cryptococcus), and viral (including HSV) infections while awaiting further data ( Table 2 ). Bactericidal or fungicidal agents with CNS penetration are preferred. Broad-spectrum coverage is maintained until a diagnosis is achieved. The management of immunosuppression is individualized, such as reducing T-cell suppression in viral infections including EBV-associated PTLD or JC virus-induced PML [123] . Reduced immunosuppression risks immunologic rebound with graft rejection, increased inflammation and edema, and/ or immune reconstitution inflammatory syndrome (IRIS) manifesting as worsening of CNS symptoms in the face of appropriate therapy and without disease progression [124] . IRIS has been documented in transplant recipients with CMV, tuberculosis, and cryptococcal disease [125, 126] . Acute reductions in corticosteroids during CNS infection, in particular, may provoke hydrocephalus in cryptococcal meningitis or flares of infectious vasculitis or encephalitis [126] . CNS PTLD may not respond to reduced immunosuppression; irradiation is often beneficial and CD20 + tumors may respond to antibody therapy. Immunosuppression must be reinstated when appropriate to avoid graft rejection. Increases in immunosuppression may be helpful, particularly for specific pathogens such as S. pneumoniae [31] . Increased adrenocorticoids may reverse persistent hypotension due to adrenal insufficiency from infection or chronic glucocorticoid use [127, 128] . CNS toxicity of CNI is common. The in vivo benefits of the in vitro synergy between calcineurin inhibitors and antifungal agents for cryptococcosis and the Mucorales remain to be demonstrated [129, 130] .
Some transplant recipients require procedural interventions for management of CNS infection. Cryptococcal meningitis may cause elevated intracranial pressure with hydrocephalus requiring serial lumbar punctures or ventricular shunting [107, 131, 132] . Surgical neurosurgical intervention may be required for acute hydrocephalus due to intraventricular development or rupture of abscesses blocking CSF ventricular flow [133] .
Surgical debridement of bacterial abscesses or fungal lesions (eg, Mucorales) may be required for diagnosis and to gain control of progressive, invasive infection.
CONCLUSIONS
Transplant recipients have a high incidence of symptoms attributable to the CNS. Multiple processes can account for CNS dysfunction; patients are vulnerable to concurrent infectious and noninfectious processes. Consideration should be given to unique epidemiologic exposures, immunosuppression, metabolic abnormalities, and drug effects. Clinical symptoms and physical findings are often poor guides to specific processes. Given the potential for rapid disease progression if untreated, a specific etiologic diagnosis should be aggressively pursued while empiric therapy is introduced.
